Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders
View Patent ↗The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders.
1. A method for blocking the development or treating or reducing the severity or effects of systemic lupus erythematosus in an animal comprising the step of administering a pharmaceutical composition which comprises a therapeutically effective amount of an antibody that binds to a TWEAK polypeptide consisting of SEQ ID NO:1 or SEQ ID NO:2.
2. The method according to claim 1 , wherein the animal is mammalian.
3. The method according to claim 2 , wherein the mammal is human.
4. The method of claim 1 , wherein the antibody binds to the human TWEAK polypeptide consisting of SEQ ID NO:2.
5. The method of claim 4 , wherein the antibody is a monoclonal antibody.
6. The method of claim 5 , wherein the monoclonal antibody is a monoclonal antibody produced by a hybridoma.
7. The method of claim 6 , wherein the monoclonal antibody is an AB.D3 monoclonal antibody produced by a hybridoma having ATCC Accession No. HB-12622.
8. The method of claim 4 , wherein the antibody is a recombinant antibody.
9. The method of claim 8 , wherein the antibody is a humanized antibody.
10. The method of claim 9 , wherein the humanized antibody is a chimera of antibody AB.D3 produced by a hybridoma having ATCC Accession No. HB-12622.
11. The method of claim 4 , wherein the antibody comprises variable domains of antibody AB.D3 produced by a hybridoma having ATCC Accession No. HB-12622.
12. The method of claim 4 , wherein the antibody comprises a human constant domain.
13. The method of claim 4 , wherein the antibody is an IgG.
14. The method of claim 4 , wherein the antibody is administered by a parenteral, subcutaneous, or intravenous route.
15. The method of claim 4 , wherein the antibody is administered as a liquid composition.
16. The method of claim 15 , wherein the liquid composition is a sterile, isotonic composition.
17. The method of claim 4 , wherein the antibody blocks the binding of human TWEAK-Flag polypeptide to HT29 cells.
18. The method of claim 4 , wherein the antibody also binds to a polypeptide consisting of SEQ ID NO:1.
19. The method of claim 9 , wherein the humanized antibody comprises variable domains identical to the variable domains of antibody AB.D3 produced by the hybridoma deposited with ATCC under Accession No. HB-12622.